Background Optimal strategies for advanced hepatocellular carcinoma (HCC) tumors, such
as those with vascular tumor thrombus and those with extrahepatic metastases are unclear …

Background: Combined therapy with tyrosine kinase inhibitors (TKIs) and anti-PD-1
antibodies has shown high tumor response rates for patients with unresectable …

Sorafenib, an orally-available kinase inhibitor, is the only medical treatment with a proven
efficacy against Hepatocellular Carcinoma (HCC). Although the overall clinical efficacy of …

Purpose We aimed to investigate the feasibility of lenvatinib plus anti-PD-1 therapy as a
conversion therapy for initially unresectable hepatocellular carcinoma (HCC). Methods …

Objectives There has been increased interest in the possible role of human cytomegalovirus
(HCMV) in carcinogenesis during the last decade. HCMV seroprevalence was enhanced in …

Management of advanced hepatocellular carcinoma (HCC), one of the most lethal cancers
worldwide, has presented a therapeutic challenge over past decades. Most patients with …

Novel molecular therapies using targeted drugs and immune checkpoint inhibitors for
advanced hepatocellular carcinoma have been evolving. Sorafenib and lenvatinib have …

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths
worldwide. In China, most HCC patients are diagnosed with advanced disease and in these …

Background/Aim: We report the outcomes of sorafenib therapy for advanced hepatocellular
carcinoma (HCC) in our Department. Patients and Methods: Thirty-eight patients with …

Methods In total, 523 patients with advanced HCC were treated with sorafenib in 3 large
tertiary referral hospitals in Korea. A survey was conducted to collect data on patients who …